Back

ATTRibute-CM: acoramidis (AG10) in patients with transthyretin amyloid cardiomyopathy

27 August 2023 (11:15 - 11:25)
Organised by: Logo
Congress Presentation Part of: HOT LINE 5 Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Julian Gillmore

UCL, Greater London (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
Discussant review - ATTRibute-CM
Professor T. Damy (Creteil, FR)
Slides Video
Presentation thumbnail
Panel discussion - ATTRibute-CM
Video
Presentation thumbnail
ARREST trial: Expedited transfer to a cardiac arrest center for OHCA
Doctor T. Patterson (London, GB)
Slides Video
Presentation thumbnail
Discussant review - ARREST
Associate Professor L. Crotti (Milan, IT)
Slides Video
Presentation thumbnail
Panel discussion - ARREST
Video

Access the full session

Session thumbnail
HOT LINE 5
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM
thumbnail
Congress Presentation
Acoramidis-mediated improvement in NT-proBNP at month 30 compared with placebo in patients with ATTR-CM: results from the ATTRibute-CM study
thumbnail
Congress Presentation
Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources